In this article, we add to our increasing belief that Calumet Specialty Products Partners' (CLMT) has a bright future with an extremely undervalued stock price. We believe that there are factors worth of profits for the patient. (Our name is more than a name.) Our revenue model once again predicted reasonably close Calumet's 1st Quarter financial performance making this the second quarter in a row. Are we on to something or too presumptuous?
For us predicting closely timed, quarter over quarter, financial performance is the first critical leg. The second leg is adding viable market